Advances in Hyperkalemia Management: Implications for Patients and Providers
Credit(s): 1.00 (60 min)
Release Date: Sep 30, 2019
Expiration Date: Sep 30, 2020
CME / AMA PRA Category 1 Credit™
MOC / ABIM MOC Part 2 Credit
Conventional treatment of hyperkalemia is restricted by adverse events, as well as a dearth of evidence supporting clinical use (specifically with sodium polystyrene sulfonate). For medication-induced hyperkalemia, treatment involves a dose decrease or discontinuation of the offending agent (usually a renin-angiotensin-aldosterone system inhibitor [RAASI]); however, this often prevents patients from receiving appropriate guideline-directed management. Recent research has led to the development of two novel potassium binders with good safety profiles that allow patients to maintain or increase the use of RAASIs for cardio- and reno-protection.
This CME activity, Advances in Hyperkalemia Management: Implications for Patients and Providers, will help participating clinicians identify those patient populations most likely to present with or develop hyperkalemia, and utilize the appropriate conventional and/or novel agents to correct subacute hyperkalemia.
Welcome and Introductions
Understanding the Current Subacute/Chronic Hyperkalemia Armamentarium
Improving the Care of Adults with and at Risk for Hyperkalemia
Q&A Session and Activity Roundup
This activity is intended for physicians, hospitalists, nephrologists, and cardiologists involved in the management and education of adults with or at risk for hyperkalemia.
At the conclusion of this activity, participants should be able to:
Compare and contrast safety and efficacy data on novel and conventional agents for correcting subacute/chronic hyperkalemia
Identify patient populations likely to present with or develop hyperkalemia
Incorporate novel agents for correcting subacute hyperkalemia into patient care plans
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MedChi, The Maryland State Medical Society, and Rockpointe. MedChi is accredited by the ACCME to provide continuing medical education for physicians.
MedChi designates this online web-based activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit or the evaluation, please email firstname.lastname@example.org.
ABIM MOC DESIGNATION
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through MedChi’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
Javed Butler, MD, MPH, MBA
Professor and Chairman
Department of Medicine
University of Mississippi
Javed Butler, MD, MPH, MBA, is the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi Medical Center in Jackson, MS. He is also Professor of Physiology. Prior to joining the University of Mississippi, he was Charles A. Gargano Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University in New York. He had served as the Director for Heart Failure research at Emory University and Director of the Heart and Heart-Lung Transplant programs at Vanderbilt University.
He completed residency training at Yale University, cardiology and advanced heart failure and transplant fellowships at Vanderbilt University, and a cardiac imaging fellowship at the Massachusetts General Hospital at the Harvard Medical School. He completed his Master of Public Health degree from Harvard University and Master in Business Administration from Emory University.
Dr. Butler is board certified in advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award from the American College of Cardiology as well as the Time, Feeling, and Focus Award from the American Heart Association.
Dr. Butler has authored more than 550 peer-reviewed publications. He serves on the editorial board of several peer-reviewed cardiovascular journals. He has been cited numerous times in America’s Best Doctors list.
Biff F. Palmer, MD
Professor of Internal Medicine
Distinguished Teaching Professor
University of Texas Southwestern Medical Center
Biff F. Palmer, MD, is a tenured Professor of Internal Medicine at the University of Texas Southwestern Medical Center in Dallas, TX. He is board-certified in internal medicine and nephrology. Dr. Palmer received his medical degree from UT Southwestern Medical School and completed his residency in internal medicine at Walter Reed Army Medical Center in Washington, DC. He then went on to complete a research fellowship in the Department of Nephrology at the Walter Reed Army Institute of Research and a clinical fellowship in the Division of Nephrology at UT Southwestern Medical Center-Parkland Memorial Hospital.
Dr. Palmer has authored more than 240 articles and chapters. In addition to his work as an author, Dr. Palmer has served as the Program Director for the Renal Fellowship Program and as an Associate Program Director for the Internal Medicine Residency Program at UT Southwestern. He is an Associate Editor for the American Journal of Nephrology and is on the editorial board of Clinical Nephrology, Clinical Journal of the American Society of Nephrology, and the American Journal of Kidney Disease. He served for six years on the nephrology subspecialty board for the American Board of Internal Medicine.
He has received numerous teaching awards, including the Regents Outstanding Teaching Award from the University of Texas and the Parkland Memorial Hospital Internal Medicine Housestaff Outstanding Teacher Award. He is a member of the Southwestern Academy of Teachers and the University of Texas Kenneth I. Shine Academy of Health Science Education. He is designated as a Distinguished Teaching Professor by the University.
MedChi, The Maryland State Medical Society, (MedChi) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, andscientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by MedChi are required to disclose any relevant financial relationships with any commercial interest to MedChi as well as to learners. All conflicts of interest are identified and resolved by MedChi in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.
The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Nicolle Rochino, PharmD, RPh; Blair St. Amand; Frank C. Berry; Steven F. Crawford, MD: Nothing to disclose
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an internet browser capable of playing an HTML5 video.
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test, with a score of 66% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.
Jointly provided by MedChi and Rockpointe
This program is supported by an unrestricted educational grant from AstraZeneca.
Clicking Start Activity indicates that you have reviewed the CME/CE information for this activity
Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS)
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.